{ "completed": true, "status": "completed_original_source_reconciliation", "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings", "queries": [ "https://consensus.app/search/retatrutide-clinical-trial-analysis/11vWq7mLT7yQ4fV1S4bsUw/" ], "query_record_note": "Exact visible question/response retained privately in raw browser receipt.", "primary_comparison_count": 9, "primary_comparisons": [ { "pmid": "37366315", "doi": "10.1056/NEJMoa2301972", "source_type": "primary study report", "study_group": "RETAT-NCT04881760", "access_depth": "abstract_metadata", "consensus_aspect": "Consensus identifies placebo-controlled phase2 weight efficacy and dose/tolerability.", "result_comparison": "Original abstract agrees with338randomized adults,24-week primary and48-week secondary weights and high-dose5%responders. This supports trial efficacy, not a modern active-comparator superiority claim. Fulltrial Methods/supplementwere not fully audited.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/37366315/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [] }, { "pmid": "42250575", "doi": "10.1016/S0140-6736(26)00967-0", "source_type": "primary study report", "study_group": "RETAT-NCT06354660", "access_depth": "abstract_metadata", "consensus_aspect": "Provider reports40-week TRANSCEND-T2D-1 phase3 weight results and completion.", "result_comparison": "Original abstract confirms537participants and treatment-regimen weight change−11.5%to−15.3%versus−2.6%placebo. Primary endpointisHbA1c and entryBMI≥23; whole-cohort weights do not exactly estimate the preregistered obesity/overweight subset.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/42250575/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [] }, { "pmid": "42814954", "doi": "10.1056/NEJMoa2604169", "source_type": "primary study report", "study_group": "RETAT-NCT05929066", "access_depth": "abstract_metadata", "consensus_aspect": "Consensus does not retrieve the named2026TRIUMPH1results and instead cites the2025designpaper.", "result_comparison": "Original PMID42814954 confirms peer-reviewed29September2026results,2339randomizedparticipants and80-week treatment-regimen weights up to−25.0%versus−3.9%placebo. Provider corpus omission is not absenceofpublication.80weeks is longer-horizon corroboration beyond our registered24–72weeks. IndexedOSA sign inconsistency is flagged without repeatingthatnumber.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/42814954/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-56-62-6000.json" ], "body_receipts": [] }, { "pmid": "42810372", "doi": "10.1016/S0140-6736(26)01861-1", "source_type": "primary study report", "study_group": "RETAT-NCT05929079", "access_depth": "abstract_metadata", "consensus_aspect": "Provider similarly lacks indexedTRIUMPH2resulttext.", "result_comparison": "Original PMID42810372 confirms1152randomized adults withBMI≥27andT2D, multiple-imputation treatment-regimen weight results at80weeks and tolerability signals. This resultisavailablebeforecutoff; provider gap cannotbe called a researchgap.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/42810372/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [] }, { "pmid": "37385280", "doi": "10.1016/S0140-6736(23)01053-X", "source_type": "primary study report", "study_group": "RETAT-NCT04867785", "access_depth": "abstract_metadata", "consensus_aspect": "Consensus distinguishes older dulaglutide active comparison from obesity-standard comparator evidence.", "result_comparison": "Original randomized double-dummy phase2 report confirms36-week retatrutideweight loss beyond dulaglutide1.5mg atdoses≥4mg, but cannot establish superiorityoverobesity-dose semaglutide/tirzepatide.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/37385280/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [] }, { "pmid": "40916752", "doi": "10.1111/dom.70097", "source_type": "primary study report", "study_group": "RETAT-NCT04867785", "access_depth": "full_text_partial", "consensus_aspect": "Provider suggests appetite modification contributes to weight loss.", "result_comparison": "Selected original Methods/Results retain self-reportedhigher-dose hunger effects, but satiety/fullness and aggregate appetite-to-weight correlations are oftennull. These are samephase2participants, not a newtrial or proof of receptor-specific mediation.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/40916752/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\body-presentation-receipts\\40916752-s1-p0-2.json", "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\body-presentation-receipts\\40916752-s4-p0-2-5-7-14.json" ] }, { "pmid": "42608321", "doi": "10.1111/dom.71200", "source_type": "primary study report", "study_group": "RETAT-PHASE2-POOLED", "access_depth": "full_text_partial", "consensus_aspect": "Consensus describes lipid remodeling andmechanistic humanfollow-up.", "result_comparison": "Selected originalbodyconfirms post-hoc phase2analyses and exclusionofpost-discontinuation/rescue samples. Inflammationcontrasts are nonsignificant inT2D but somepositive in non-diabetes. Surrogates are not hardcardiovascularoutcomes or independentclinicalcausallines.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/42608321/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\body-presentation-receipts\\42608321-s1-p0-2-3.json", "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\body-presentation-receipts\\42608321-s2-p0-12-14.json" ] }, { "pmid": "39509151", "doi": "10.2196/65440", "source_type": "primary study report", "study_group": "SEMAGLUTIDE-ONLINE-PURCHASES-2023", "access_depth": "full_text_partial", "consensus_aspect": "Provider reports no direct retatrutide online-vialquality data initscorpus.", "result_comparison": "Our original class-product testing issemaglutide, notretatrutide, andhighest-risk vendor sampling islimited. Results report upper-bound endotoxinvalues fortwo samples and anelevatedmeasuredvalueforone despiteabstractbroadwording. Suchdataestablishesfailuremodes, not everyretatrutidevialquality.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/39509151/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-56-62-6000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\body-presentation-receipts\\39509151-s1-p0-7-11-12.json", "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\body-presentation-receipts\\39509151-s2-p21-27-28-32.json" ] }, { "pmid": "40609566", "doi": "10.1016/S2213-8587(25)00092-0", "source_type": "primary study report", "study_group": "RETAT-NCT04867785", "access_depth": "abstract_metadata", "consensus_aspect": "Provider calls bodycomposition andweight-quality outcomesunderdeveloped.", "result_comparison": "Original2025retatrutideDXAsubstudyexists andshows higher-dosefat-massreduction, but only103completed bothscans. Leanmassproportions do notprove musclefunction or absenceofsarcopenia; thissamephase2trialdoesnotcreateanindependence line.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/40609566/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\examinations\\original-0-8-6000.json" ], "body_receipts": [] } ], "grade_changed": false, "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.", "raw_receipts": [ { "path": "deliverables\\hsef_v53_traffic_first_five_2026-10-12\\retatrutide-weight-loss\\consensus-browser-2026-10-12.json", "sha256": "55b772ed5c7cf0f9f3aaecb879cd2571f6ad0637a3d19a4083cc2732d9ffcdb3" } ], "independent_blinded_audit": false, "cutoff": "2026-10-12", "completed_utc": "2026-10-13T06:24:59.082675+00:00", "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them." }